Table of Contents

company-logo

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Aldeyra Therapeutics Dividend Announcement

• Aldeyra Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Aldeyra Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Aldeyra Therapeutics Dividend History

Aldeyra Therapeutics Dividend Yield

Aldeyra Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Aldeyra Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Aldeyra Therapeutics Financial Ratios

P/E ratio-6.95
PEG ratio0.51
P/B ratio3.66
ROE-43.01%
Payout ratio0.00%
Current ratio6.80
Quick ratio6.80
Cash Ratio1.64

Aldeyra Therapeutics Dividend FAQ

Does Aldeyra Therapeutics stock pay dividends?
Aldeyra Therapeutics does not currently pay dividends to its shareholders.
Has Aldeyra Therapeutics ever paid a dividend?
No, Aldeyra Therapeutics has no a history of paying dividends to its shareholders. Aldeyra Therapeutics is not known for its dividend payments.
Why doesn't Aldeyra Therapeutics pay dividends?
There are several potential reasons why Aldeyra Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Aldeyra Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Aldeyra Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Aldeyra Therapeutics a dividend aristocrat?
Aldeyra Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Aldeyra Therapeutics a dividend king?
Aldeyra Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Aldeyra Therapeutics a dividend stock?
No, Aldeyra Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Aldeyra Therapeutics stocks?
To buy Aldeyra Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Aldeyra Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.